1. Novel antibodies targeting immune regulatory checkpoints for cancer therapy
2. Naing A, Gelderblom H, Gainor J, Forde PM, Butler M, Lin CC, Sharma S, Ochoa de Olza M, Schellens JHM, Soria JC. A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors. 2016 ASCO Annual Meeting, Poster Discussion. J Clin Oncol 2016;34 Suppl:abstr 3060.
3. Eli Lilly and Company. A study of anti-PD-L1 checkpoint antibody (LY3300054) alone and in combination in participants with advanced refractory solid tumors (PACT). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: https://clinicaltrials.gov/ct2/show/NCT02791334.
4. Bristol-Myers Squibb. Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: https://clinicaltrials.gov/ct2/show/NCT02534506.
5. The blockade of immune checkpoints in cancer immunotherapy